# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001714899-22-000014
Filing Date
2022-01-10
Accepted
2022-01-10 09:06:06
Documents
14
Period of Report
2022-01-10
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 8-K | dnli-20220110.htm iXBRL | 8-K | 40283
2 | EX-99.1 | ex991pressrelease1102022.htm | EX-99.1 | 53787
6 |  | denali_txlogox02.jpg | GRAPHIC | 680367
| Complete submission text file | 0001714899-22-000014.txt |  | 1172119

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
3 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | dnli-20220110.xsd | EX-101.SCH | 1932
4 | XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | dnli-20220110_lab.xml | EX-101.LAB | 23832
5 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT | dnli-20220110_pre.xml | EX-101.PRE | 12528
8 | EXTRACTED XBRL INSTANCE DOCUMENT | dnli-20220110_htm.xml | XML | 10900

Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 22519972
SIC: 2836 Biological Products, (No Diagnostic Substances)